Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Information sources -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (27)	6/27/2003 7:35:52 PM
From: Icebrg	Read Replies (1) \| Respond to of 269

Newratings A webservice which provides a free update of analyst's ratings, with some small comments. The service is free In addition there is also a 10 USD per month pay service. newratings.com Sample from free service: Cubist Pharmaceuticals initiated with "buy" - update Updated Friday, June 27, 2003 8:33:33 AM ET First Albany NEW YORK, June 27 (New Ratings) - Analysts at First Albany initiate coverage of Cubist Pharmaceuticals with a "buy" rating. The target price is set to $14. In a research note published this morning, the analysts mention that Cidecin, an antibiotic for skin and skin structure infections has successfully completed Phase III trials. The analysts expect the FDA approval in September and the commercial launch of the drug by 4Q03. According to First Albany, the company must ensure that it has enough inventories to successfully launch the new drug without delay.